Fundraising Fox
/Companies
Sign in

NovalGen

London, GB · Founded 2019 · 11 employees on LinkedIn · 2 known investors

Find your way into NovalGen

Sign up to see every warm intro you have to NovalGen

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the NovalGen team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

NovalGen is a clinical-stage biotechnology company developing multi-specific biologics for oncology, autoimmune, haematological, and metabolic disorders using its proprietary AutoRegulation platform technology.

BiotechHealthtechLongevityMedical Devices

Investors · 2

UCL Technology Fundlisted by UCL Technology FundLondon · $320K – $9M

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Companies House · registry record

View on Companies House ↗
Registered name
NOVALGEN LIMITED
Company number
11621264
Status
Active
Company type
Private limited company
Incorporated
14 Oct 2018
Registered office
Argyle House Level 3 Northside, Joel Street, Northwood Hills, Middlesex, HA6 1NW
Nature of business (SIC)
72110 — Research and experimental development on biotechnology
Previous names
IMMUNOCURE LIMITED (2018–2018)
Accounts
last made up to 31 Dec 2025 · next due 30 Sept 2027
Confirmation statement
last made up to 13 Oct 2025 · next due 27 Oct 2026

Current officers · 7

  • Scott Clarke — director, appointed 9 Dec 2022
  • Samit Govindji Hathi — director, appointed 7 Jan 2019
  • Amit Chunilal Nathwani — director, appointed 6 Jan 2020
  • Michael Owen — director, appointed 3 Jan 2023
  • Bharat Kumar Hirji Thakrar — director, appointed 7 Jan 2019
  • David Charles Venables — director, appointed 24 Mar 2023
  • Ucltf Corporate Directors Ltd — corporate director, appointed 15 Feb 2023

Source: Companies House public register · retrieved 6 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.

Frequently asked questions

What does NovalGen do?
NovalGen is a clinical-stage biotechnology company developing multi-specific biologics for oncology, autoimmune, haematological, and metabolic disorders using its proprietary AutoRegulation platform technology.
Who are NovalGen's investors?
NovalGen's investors include AlbionVC, UCL Technology Fund.
Where is NovalGen headquartered?
NovalGen is headquartered in London, GB.